Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Net Income (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Net Income for 4 consecutive years, with -$12.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 80.87% to -$12.2 million in Q3 2025 year-over-year; TTM through Dec 2025 was -$8.5 million, a 86.73% increase, with the full-year FY2011 number at -$116.2 million, down 14.19% from a year prior.
  • Net Income was -$12.2 million for Q3 2025 at Lexicon Pharmaceuticals, down from $3.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $3.7 million in Q2 2025 to a low of -$63.7 million in Q3 2024.